Submitted:
19 March 2026
Posted:
23 March 2026
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Results
2.1. Structural Characterization

2.2. Biological Assay
2.3. Pharmacological Network and Molecular Modeling
3. Materials and Methods
3.1. General Experimental Procedures
3.2. Plant Material
3.3. Extraction and Isolation
3.4. Cytotoxicity Assay
3.5. Network Pharmacology
3.6. Molecular Docking
| Targets | PDB (ID) | Resolution | Ligands | Reference |
| ERα* | 1XP1 | 1.80 Å | Compound 15 | [38] |
| ERβ** | 1X76 | 2.20 Å | WAY-697 | [39] |
| HER2*** | 3PP0 | 2.25 Å | SYR127063 | [40] |
| HSP90α**** | 1UYF | 2.00 Å | PU3 | [41] |
| PI3Kγ***** | 4HVB | 2.35 Å | PF-04979064 | [42] |
3.7. Molecular Dynamics
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| MDPI | Multidisciplinary Digital Publishing Institute |
| DOAJ | Directory of open access journals |
| TLA | Three letter acronyms |
| LD | Linear dichroism |
References
- Cavalcante, N.B.; Diego da Conceição Santos, A.; Guedes da Silva Almeida, J.R. The Genus Jatropha (Euphorbiaceae): A Review on Secondary Chemical Metabolites and Biological Aspects. Chem. Biol. Interact. 2020, 318, 108976. [Google Scholar] [CrossRef] [PubMed]
- Agra, M. de F.; de Freitas, P.F.; Barbosa-Filho, J.M. Synopsis of the Plants Known as Medicinal and Poisonous in Northeast of Brazil. Revista Brasileira de Farmacognosia 2007, 17, 114–140. [Google Scholar] [CrossRef]
- Pinto, M.E.F.; Batista, J.M.; Koehbach, J.; Gaur, P.; Sharma, A.; Nakabashi, M.; Cilli, E.M.; Giesel, G.M.; Verli, H.; Gruber, C.W.; et al. Ribifolin, an Orbitide from Jatropha Ribifolia, and Its Potential Antimalarial Activity. J. Nat. Prod. 2015, 78, 374–380. [Google Scholar] [CrossRef] [PubMed]
- Fernandes, E. de S.; Rodrigues, F.A.; Tófoli, D.; Imamura, P.M.; de Carvalho, J.E.; Ruiz, A.L.T.G.; Foglio, M.A.; Minguzzi, S.; Silva, R.C.L. Isolation, Structural Identification and Cytotoxic Activity of Hexanic Extract, Cyperenoic Acid, and Jatrophone Terpenes from Jatropha Ribifolia Roots. Revista Brasileira de Farmacognosia 2013, 23, 441–446. [Google Scholar] [CrossRef]
- A. de Souza, T.; F. Alves, A.; D. T. Lira, N.; P. Cibulski, S.; H. A. Pereira, L.; S. Abreu, L.; F. Tavares, J.; T. Scotti, M.; da Silva, S.; M. Chemotaxonomic Analysis of Diterpenes in Four Euphorbiaceae Genera: A Path to New Cytotoxic Agents. J. Braz. Chem. Soc. 2025. [Google Scholar] [CrossRef]
- Liu, Y.; Zhang, S.; Liu, K.; Hu, X.; Gu, X. Advances in Drug Discovery Based on Network Pharmacology and Omics Technology. Curr. Pharm. Anal. 2024, 21, 33–43. [Google Scholar] [CrossRef]
- Li, L.; Kar, S. Leveraging Network Pharmacology for Drug Discovery: Integrative Approaches and Emerging Insights. Med. Drug Discov. 2025, 27, 100220. [Google Scholar] [CrossRef]
- Zhou, Z.; Chen, B.; Chen, S.; Lin, M.; Chen, Y.; Jin, S.; Chen, W.; Zhang, Y. Applications of Network Pharmacology in Traditional Chinese Medicine Research. In Evidence-Based Complementary and Alternative Medicine; 2020. [Google Scholar] [CrossRef]
- Yang, J.; Long, Y.O.; Paquette, L.A. Concise Total Syntheses of the Bioactive Mesotricyclic Diterpenoids Jatrophatrione and Citlalitrione. J. Am. Chem. Soc. 2003, 125, 1567–1574. [Google Scholar] [CrossRef] [PubMed]
- Pertino, M.; Schmeda-Hirschmann, G.; Rodríguez, J.A.; Theoduloz, C. Gastroprotective Effect and Cytotoxicity of Terpenes from the Paraguayan Crude Drug “Yagua Rova” (Jatropha Isabelli). J. Ethnopharmacol. 2007, 111, 553–559. [Google Scholar] [CrossRef] [PubMed]
- Taylor, M.D.; Smith, A.B.; Furst, G.T.; Gunasekara, S.P.; Bevelle, C.A.; Cordell, G.A.; Farnsworth, N.R.; Kupchan, S.M.; Uchida, H. Plant Anticancer Agents. 28. New Antileukemic Jatrophone Derivatives from Jatropha Gossypiifolia: Structural and Stereochemical Assignment through Nuclear Magnetic Resonance Spectroscopy. J. Am. Chem. Soc. 1983, 105, 3177–3183. [Google Scholar] [CrossRef]
- Kanth, B.S.; Kumar, A.S.; Shinde, D.B.; Babu, K.H.; Raju, T.V.; Kumar, C.G.; Sujitha, P.; Das, B. New Bioactive Macrocyclic Diterpenoids from Jatropha Multifida. Bioorg. Med. Chem. Lett. 2011, 21, 6808–6810. [Google Scholar] [CrossRef] [PubMed]
- Taylor, M.D.; Smith, A.B.; Furst, G.T.; Gunasekara, S.P.; Bevelle, C.A.; Cordell, G.A.; Farnsworth, N.R.; Kupchan, S.M.; Uchida, H. Plant Anticancer Agents. 28. New Antileukemic Jatrophone Derivatives from Jatropha Gossypiifolia: Structural and Stereochemical Assignment through Nuclear Magnetic Resonance Spectroscopy. J. Am. Chem. Soc. 1983, 105, 3177–3183. [Google Scholar] [CrossRef]
- Indrayanto, G.; Putra, G.S.; Suhud, F. Validation of In-Vitro Bioassay Methods: Application in Herbal Drug Research. Profiles of Drug Substances, Excipients and Related Methodology 2021, 273–307. [Google Scholar]
- Fattahian, M.; Ghanadian, M.; Ali, Z.; Khan, I.A. Jatrophane and Rearranged Jatrophane-Type Diterpenes: Biogenesis, Structure, Isolation, Biological Activity and SARs (1984–2019). Phytochemistry Reviews 2020, 19, 265–336. [Google Scholar] [CrossRef]
- Lu, Y.-B.; Luo, S.; Wang, Y.-X.; Feng, Z.-Y.; Gao, K.; Chen, J.-J. Jatrophane Diterpenoids with Cytotoxic Activity from the Whole Plant of Euphorbia Heliosocpia L. Phytochemistry 2022, 203, 113420. [Google Scholar] [CrossRef] [PubMed]
- Pešić, M.; Banković, J.; Aljančić, I.S.; Todorović, N.M.; Jadranin, M.; Vajs, V.E.; Tešević, V. V.; Vučković, I.; Momčilović, M.; Marković, I.D.; et al. New Anti-Cancer Characteristics of Jatrophane Diterpenes from Euphorbia Dendroides. Food and Chemical Toxicology 2011, 49, 3165–3173. [Google Scholar] [CrossRef]
- de Souza, T.A.; Pereira, L.H.A.; Alves, A.F.; Dourado, D.; Lins, J. da S.; Scotti, M.T.; Scotti, L.; Abreu, L.S.; Tavares, J.F.; Silva, M.S. Jatropha Diterpenes: An Updated Review Concerning Their Structural Diversity, Therapeutic Performance, and Future Pharmaceutical Applications. Pharmaceuticals 2024, 17, 1399. [Google Scholar] [CrossRef]
- Jiang, M.; Zhang, K.; Zhang, Z.; Zeng, X.; Huang, Z.; Qin, P.; Xie, Z.; Cai, X.; Ashrafizadeh, M.; Tian, Y.; et al. PI3K/AKT/MTOR Axis in Cancer: From Pathogenesis to Treatment. MedComm (Beijing). 2025, 6. [Google Scholar] [CrossRef] [PubMed]
- Glaviano, A.; Foo, A.S.C.; Lam, H.Y.; Yap, K.C.H.; Jacot, W.; Jones, R.H.; Eng, H.; Nair, M.G.; Makvandi, P.; Geoerger, B.; et al. PI3K/AKT/MTOR Signaling Transduction Pathway and Targeted Therapies in Cancer. Mol. Cancer 2023, 22, 138. [Google Scholar] [CrossRef] [PubMed]
- Paggi, J.M.; Pandit, A.; Dror, R.O. The Art and Science of Molecular Docking. Annu. Rev. Biochem. 2024, 93, 389–410. [Google Scholar] [CrossRef]
- Chen, P.; Li, B.; Ou-Yang, L. Role of Estrogen Receptors in Health and Disease. Front. Endocrinol. (Lausanne). 2022, 13. [Google Scholar] [CrossRef]
- Treneff, J.; McCrary, A.; Burd, C. Abstract 4055: Estrogen Receptor Beta Suppresses Melanoma Progression through Modulation of Melanocyte Master Regulator Activity. Cancer Res. 2025, 85. [Google Scholar] [CrossRef]
- Das, P.K.; Saha, J.; Pillai, S.; Lam, A.K. -Y.; Gopalan, V.; Islam, F. Implications of Estrogen and Its Receptors in Colorectal Carcinoma. Cancer Med. 2023, 12, 4367–4379. [Google Scholar] [CrossRef]
- Rawłuszko-Wieczorek, A.A.; Lipowicz, J.; Nowacka, M.; Ostrowska, K.; Pietras, P.; Blatkiewicz, M.; Ruciński, M.; Jagodziński, P.P.; Nowicki, M. Estrogen Receptor β Affects Hypoxia Response in Colorectal Cancer Cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024, 1870, 166894. [Google Scholar] [CrossRef] [PubMed]
- Mori, T.; Martinez, S.R.; O’Day, S.J.; Morton, D.L.; Umetani, N.; Kitago, M.; Tanemura, A.; Nguyen, S.L.; Tran, A.N.; Wang, H.-J.; et al. Estrogen Receptor-α Methylation Predicts Melanoma Progression. Cancer Res. 2006, 66, 6692–6698. [Google Scholar] [CrossRef] [PubMed]
- Roney, M.; Mohd Aluwi, M.F.F. The Importance of In-Silico Studies in Drug Discovery. Intelligent Pharmacy 2024, 2, 578–579. [Google Scholar] [CrossRef]
- Shah, A.; Jain, M. Limitations and Future Challenges of Computer-Aided Drug Design Methods. In Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches; Elsevier, 2022; pp. 283–297. [Google Scholar]
- Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef] [PubMed]
- de Sousa, V.M.; Duarte, S.S.; Ferreira, R.C.; de Sousa, N.F.; Scotti, M.T.; Scotti, L.; da Silva, M.S.; Tavares, J.F.; de Moura, R.O.; Gonçalves, J.C.R.; et al. AMTAC-19, a Spiro-Acridine Compound, Induces In Vitro Antitumor Effect via the ROS-ERK/JNK Signaling Pathway. Molecules 2024, 29, 5344. [Google Scholar] [CrossRef] [PubMed]
- de Morais Melo, L.F.; de Oliveira Filho, L.P.; Ferreira, U. de A.; Pessoa Alves, E.H.; Oliveira Costa, R.P.; Scotti, L.; Scotti, M.T. AmIActive (AIA): A Large-Scale QSAR Based Target Fishing and Polypharmacology Predictive Web Tool. J. Mol. Biol. 2025, 437, 169090. [Google Scholar] [CrossRef]
- Wang, X.; Shen, Y.; Wang, S.; Li, S.; Zhang, W.; Liu, X.; Lai, L.; Pei, J.; Li, H. PharmMapper 2017 Update: A Web Server for Potential Drug Target Identification with a Comprehensive Target Pharmacophore Database. Nucleic Acids Res. 2017, 45, W356–W360. [Google Scholar] [CrossRef]
- Stelzer, G.; Rosen, N.; Plaschkes, I.; Zimmerman, S.; Twik, M.; Fishilevich, S.; Stein, T.I.; Nudel, R.; Lieder, I.; Mazor, Y.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr. Protoc. Bioinformatics 2016, 54. [Google Scholar] [CrossRef] [PubMed]
- Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K.P.; et al. STRING V10: Protein-Protein Interaction Networks, Integrated over the Tree of Life. Nucleic Acids Res. 2015, 43, D447–52. [Google Scholar] [CrossRef]
- Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef]
- Kanehisa, M. The KEGG Database. Novartis Found. Symp. 2002, 247 101-3, 91–101 119–128, 244–252. [Google Scholar]
- Wu, T.; Hu, E.; Xu, S.; Chen, M.; Guo, P.; Dai, Z.; Feng, T.; Zhou, L.; Tang, W.; Zhan, L.; et al. ClusterProfiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data. Innovation (Cambridge (Mass.)) 2021, 2, 100141. [Google Scholar] [CrossRef] [PubMed]
- Blizzard, T.A.; DiNinno, F.; Morgan, J.D.; Chen, H.Y.; Wu, J.Y.; Kim, S.; Chan, W.; Birzin, E.T.; Yang, Y.T.; Pai, L.-Y.; et al. Estrogen Receptor Ligands. Part 9: Dihydrobenzoxathiin SERAMs with Alkyl Substituted Pyrrolidine Side Chains and Linkers. Bioorg. Med. Chem. Lett. 2005, 15, 107–113. [Google Scholar] [CrossRef]
- Manas, E.S.; Unwalla, R.J.; Xu, Z.B.; Malamas, M.S.; Miller, C.P.; Harris, H.A.; Hsiao, C.; Akopian, T.; Hum, W.-T.; Malakian, K.; et al. Structure-Based Design of Estrogen Receptor-β Selective Ligands. J. Am. Chem. Soc. 2004, 126, 15106–15119. [Google Scholar] [CrossRef]
- Aertgeerts, K.; Skene, R.; Yano, J.; Sang, B.-C.; Zou, H.; Snell, G.; Jennings, A.; Iwamoto, K.; Habuka, N.; Hirokawa, A.; et al. Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein. Journal of Biological Chemistry 2011, 286, 18756–18765. [Google Scholar] [CrossRef]
- Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; et al. Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms. Chem. Biol. 2004, 11, 775–785. [Google Scholar] [CrossRef] [PubMed]
- Cheng, H.; Li, C.; Bailey, S.; Baxi, S.M.; Goulet, L.; Guo, L.; Hoffman, J.; Jiang, Y.; Johnson, T.O.; Johnson, T.W.; et al. Discovery of the Highly Potent PI3K/MTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med. Chem. Lett. 2013, 4, 91–97. [Google Scholar] [CrossRef] [PubMed]
- CLC BIO COMPANY. Molegro Virtual Docker, Versão 6.0.1 [Software]. 2013. [Google Scholar]
- Dassault Systèmes Discovery Studio Visualizer, V21.1.0 Software. 8 2029.
- Jabeen, I.; Pleban, K.; Rinner, U.; Chiba, P.; Ecker, G.F. Structure–Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein. J. Med. Chem. 2012, 55, 3261–3273. [Google Scholar] [CrossRef] [PubMed]
- Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindahl, E. GROMACS: High Performance Molecular Simulations through Multi-Level Parallelism from Laptops to Supercomputers. SoftwareX 2015, 1–2, 19–25. [Google Scholar] [CrossRef]
- Schmid, N.; Eichenberger, A.P.; Choutko, A.; Riniker, S.; Winger, M.; Mark, A.E.; van Gunsteren, W.F. Definition and Testing of the GROMOS Force-Field Versions 54A7 and 54B7. European Biophysics Journal 2011, 40, 843–856. [Google Scholar] [CrossRef]





| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| Position | δH | δH | δH | δH | δH | δH | δH | δH |
| 1α | 2.22 dd (14.4; 8.4) |
2.43 m | 1.67 m | 2.6 d (12) | 2.99 dt (1.6) | 1.24 d (13.3) | 2.11 m | 1.9 m |
| 1β | 1.89 d (14.4) | 2.11 d (4.4) | 2.04 dd (14.3; 8.3) | 2.2 d (12) | 2.83 m | 1.64-1.54 m | 2.71 m | 2.1 m |
| 2 | 2.38 m | 2.99 m | 2.48 dd | - | - | 2.12-2.06 m | 2.12-2.08 m | 2.32 m |
| 3 | 3.34 s | 6.15 d (2.0) | 3.20 m | 6.10 s | 6.6 s | 3.16 sl | 4.27 d (4.0) | 4.05 d (3,6) |
| 4 | - | - | - | - | - | - | - | |
| 5 | 5.63 ql (1.3) | 6.51 s | 5.74 dd (3.22. 1.6) | 6.11 bs | 6.3 bs | 5.24 ql (1.6) | 5.99 s | 5.7 sl |
| 6 | - | - | - | - | - | - | - | |
| 7 | - | - | - | - | - | - | - | |
| 8 | 3.82 d (11.3) | 3.31 d (1.6) | 6.23 d (16.5) | 6.0 d (13.2) | 6.01 d (12.0) | 2.56-2.50 m | 2.78 d 2.81 d (1.6) |
2.83 dd 2.75 dd |
| 9 | 4.05 d (11.3) | 4.81 t | 6.41 d (16.5) | 6.5 d (13.2) | 6.54 d (12.0) | 2.84 dd (10.0; 1.7) |
2.59 d (2.0) | 1.73 m |
| 10 | - | - | - | - | - | - | - | |
| 11α | 2.13 d (15.3) | 2.30 dd (1.6; 1.6) |
2.48 dd (0.8; 0.8) |
2.7 d (12.0) | 2.80 m | 2.43 d (16.0) | 2.49 d (10.8) | 2.0 d (12) |
| 11β | 1.86 d (15.3) | 2.60 d (13.6) | 2.86 d (14.8) | 2.4 d (12.0) | 2.50 m | 2.24 d (16.0) | 2.23 d (12.8) | |
| 12 | - | - | - | - | - | - | - | - |
| 13 | - | - | - | - | - | - | - | - |
| 14 | - | - | - | - | - | - | - | - |
| 15 | - | - | - | - | - | 3.41 dd (10.0; 7.5) |
- | - |
| 16 | 1.12 d (6.6) | 1.06 d (5.6) | 1.20 d (7.6) | 1.65 s | 5.10 bt (1.6) 5.25 bt (1.6) |
1.05 d (7.5) | 1.14 d (5.2) | 1.1 sl |
| 17 | 1.83 d (1.3) | 1.98 d (1.5) | 1.83 d (1.5) | 1.95 d (1.3) | 1.98 d (0.8) | 1.90 d (1.6) | 1.95 d (1.5) | 1.30 s |
| 18 | 1.11 s | 0.94 s | 1.22 s | 1.21 s | 1.23 s | 1.21 s | 1.28s | 1.41 s |
| 19 | 1.13 s | 1.22 s | 1.41 s | 1.33 s | 1.36 s | 0.84 s | 0.88s | 1.39 s |
| 20 | 1.16 s | 1.52 s | 1.70 d (0.7) | 1.73 s | 1.77 s | 1.34 s | 1.32 s | 1,78 s |
| Compounds | IC50 (µM) | ||
| Cell lines | |||
| SK-MEL-28 | HCT-116 | HEK-293 | |
| ribifolone A | 32.25 ± 2.41 | > 100.0 | > 100.0 |
| ribifolone B | > 100.0 | > 100.0 | - |
| ribifolone C | 50.71 ± 3.80 | 33.39 ± 1.98 | > 100.0 |
| ribifolone D | 95.64 ± 1.51 | 75.35 ± 4.82 | > 100.0 |
| ribifolone E | > 100.0 | > 100.0 | - |
| ribifolone F | > 100.0 | > 100.0 | - |
| ribifolone G | > 100.0 | > 100.0 | - |
| ribifolone H | > 100.0 | > 100.0 | - |
| jatrophone | 6.19 ± 0.96 | 10.09 ± 0.61 | 20.28 ± 0.98 |
| Protein | Ligand | Moldock Score | LE | RMSD (Å) |
| ERα | ribifolone C | -99.6025 | 4.15 | |
| jatrophone | -99.9278 | 4.34 | ||
| Compound 15 | -176.836 | 5.20 | 0.152 | |
| ERβ |
ribifolone C |
-103.407 |
4.31 |
|
| jatrophone | -106.904 | 4.65 | ||
| WAY-697 | -113.646 | 3.67 | 0.137 | |
| HER2 |
ribifolone C |
-109.498 |
4.56 |
|
| jatrophone | -109.166 | 4.75 | ||
| SYR127063 | -211.971 | 6.23 | 0.206 | |
| HSP90α |
ribifolone C |
-93.2953 |
3.89 |
|
| jatrophone | -92.7489 | 4.03 | ||
| PU3 | -133.74 | 4.46 | 0.226 | |
| PI3Kγ |
ribifolone C |
-131.08 |
2.49 |
|
| jatrophone | -133.74 | 2.36 | ||
| PF-04979064 | -133.74 | 3.86 | 0.337 |
| Molecule | Energy | Average | RMSD (Å) | Total-Drift |
| Ribifolone C |
Coulombic |
-68.839 |
30.630 |
-50.900 |
|
Lennard-Jones |
-77.920 |
16.805 |
-19.054 |
|
| Jatrophone |
Coulombic |
-25.577 |
19.671 |
18.438 |
|
Lennard-Jones |
-78.050 |
18.327 |
9.609 |
|
| WAY-697 |
Coulombic |
-158.979 |
39.815 |
-58.408 |
|
Lennard-Jones |
-51.151 |
20.575 |
-43.673 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| Position | δC | δC | δC | δC | δC | δC | δC | δC |
| 1 | 44.4 | 46.0 | 37.6 | 41.5 | 37.1 | 33.6 | 41.6 | 44.1 |
| 2 | 31.0 | 37.0 | 33.2 | 139.0 | 148.9 | 34.9 | 43.0 | 36.4 |
| 3 | 75.6 | 148.9 | 69.2 | 136.2 | 135.9 | 65.8 | 86.9 | 83.1 |
| 4 | 64.0 | 140.8 | 68.4 | 93.9 | 142.1 | 66.8 | 143.0 | 138.2 |
| 5 | 131.4 | 127.3 | 122.9 | 136.3 | 137.2 | 129.1 | 125.2 | 132.2 |
| 6 | 143.5 | 137.7 | 142.3 | 143.9 | 142.2 | 139.1 | 143.6 | 77.0 |
| 7 | 202.7 | 199.8 | 201.3 | 202.3 | 201.9 | 211.2 | 209.1 | 208.5 |
| 8 | 66.5 | 66.9 | 129.7 | 128.7 | 128.3 | 38.8 | 38.9 | 33.6 |
| 9 | 79.9 | 80.8 | 158.3 | 158.6 | 157.7 | 49.2 | 51.1 | 31.4 |
| 10 | 37.2 | 37.8 | 36.7 | 40.9 | 40.8 | 37.6 | 37.4 | 29.4 |
| 11 | 43.2 | 48.9 | 41.7 | 43.3 | 43.2 | 55.2 | 55.4 | 27.6 |
| 12 | 77.6 | 91.1 | 185.3 | 185.6 | 185.3 | 214.7 | 214.7 | 189.0 |
| 13 | 89.4 | 88.0 | 112.2 | 113.4 | 113.1 | 64.0 | 64.2 | 109.5 |
| 14 | 212.4 | 206.8 | 204.4 | 204.4 | 203.2 | 211.5 | 211.3 | 203.4 |
| 15 | 87.0 | 91.0 | 94.8 | 97.7 | 98.5 | 45.6 | 139.7 | 91.1 |
| 16 | 16.5 | 20.4 | 17.2 | 24.2 | 109.6 | 14.9 | 18.2 | 14.3 |
| 17 | 22.1 | 20.7 | 21.4 | 13.3 | 13.1 | 21.2 | 19.2 | 29.4 |
| 18 | 27.6 | 25.3 | 30.8 | 30.4 | 30.3 | 27.6 | 27.3 | 28.8 |
| 19 | 22.3 | 28.0 | 27.2 | 26.5 | 26.3 | 23.6 | 23.6 | 15.4 |
| 20 | 14.0 | 17.3 | 6.1 | 7.3 | 7.2 | 14.2 | 14.5 | 5.8 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).